- Home
- LUCD vs LUNG Comparison
LUCD vs LUNG Comparison
Compare LUCD & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- LUNG
- Stock Information
- Founded
- LUCD 2018
- LUNG 1995
- Country
- LUCD United States
- LUNG United States
- Employees
- LUCD N/A
- LUNG N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- LUNG Industrial Specialties
- Sector
- LUCD Health Care
- LUNG Health Care
- Exchange
- LUCD Nasdaq
- LUNG Nasdaq
- Market Cap
- LUCD 112.5M
- LUNG 106.3M
- IPO Year
- LUCD 2021
- LUNG 2020
- Fundamental
- Price
- LUCD $1.11
- LUNG $3.34
- Analyst Decision
- LUCD Strong Buy
- LUNG Buy
- Analyst Count
- LUCD 4
- LUNG 6
- Target Price
- LUCD $3.94
- LUNG $11.53
- AVG Volume (30 Days)
- LUCD 1.5M
- LUNG 420.0K
- Earning Date
- LUCD 08-11-2025
- LUNG 07-30-2025
- Dividend Yield
- LUCD N/A
- LUNG N/A
- EPS Growth
- LUCD N/A
- LUNG N/A
- EPS
- LUCD N/A
- LUNG N/A
- Revenue
- LUCD $4,173,000.00
- LUNG $87,473,000.00
- Revenue This Year
- LUCD $49.70
- LUNG $18.02
- Revenue Next Year
- LUCD $198.20
- LUNG $18.17
- P/E Ratio
- LUCD N/A
- LUNG N/A
- Revenue Growth
- LUCD 39.89
- LUNG 19.84
- 52 Week Low
- LUCD $0.72
- LUNG $2.50
- 52 Week High
- LUCD $1.80
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- LUCD 44.54
- LUNG 57.32
- Support Level
- LUCD $1.08
- LUNG $2.99
- Resistance Level
- LUCD $1.14
- LUNG $3.88
- Average True Range (ATR)
- LUCD 0.07
- LUNG 0.34
- MACD
- LUCD 0.00
- LUNG 0.10
- Stochastic Oscillator
- LUCD 41.03
- LUNG 58.46
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.